Grants per year
Grants 2006 2022
- 1 - 25 out of 49 results
- Status, start date (descending)
Active
Protocol No. P10934-CMVPS-CSP-01: Clinical Performance of the Aptima® CMV Quant Assay on the Panther® System
5/2/19 → 5/2/22
Project: Research project
Prot. CP40617 - A Phase III, Multicenter, Randomized, Double-Blind, Active-Controlled Study to Assess the Efficacy and Safety of Baloxavir Marboxil in Combination with a Neuraminidase Inhibitor versus a Neuraminidase Inhibitor Alone in Hospitalized Patien
Syneos Health, Inc., Genentech, Inc.
2/22/19 → 2/22/22
Project: Research project
Prot. Number IA-001: A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating the Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients with Serious Influenza A Infection
SGS North America Inc., Cangene Corporation
12/15/17 → 12/15/20
Project: Research project
AIC316-03-II-01 A Randomized, Open Label, Multi-Center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir Versus Foscarnet for the Treatment of Acyclovir-Resistant Mucocutaneous HSV Infections in Immunocompromised Adults (PRIOH-1)
Medpace, Inc., AiCuris Anti-infective Cures GmbH
12/1/17 → 12/1/20
Project: Research project
Protocol 9766-CL-0111 - A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species Protocol for Phase 4 Study of ASP9766
inVentiv Health Clinical, Astellas Pharma Global Development, Inc.
4/7/17 → 4/7/20
Project: Research project
PROTOCOL: SHP620-303 A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infection
PPD Development, Shire ViroPharma Incorporated
3/24/17 → 3/24/20
Project: Research project
Fixed Price Patient Care Costs
National Institute of Allergy and Infectious Diseases
7/1/16 → 6/30/21
Project: Research project
nitazoxanide
Norovirus
Patient Care
Transplants
Costs and Cost Analysis
Option One of Phase II Multi-Center, Prospective, Randomized, Double-Blind Study of Nitazoxanide in Acute and Chronic Norovirus in Hematpoietic Stem Cell and Solid Organ Transplant Recipients
National Institute of Allergy and Infectious Diseases
7/1/16 → 6/30/21
Project: Research project
nitazoxanide
Norovirus
Double-Blind Method
Stem Cells
Transplants
Phase II Multi-Center, Prospective, Randomized, Double-Blind Study of Nitazoxanide in Acute and Chronic Norovirus in Hematpoietic Stem Cell and Solid Organ Transplant Recipients
Angarone, M. P., Ison, M. G. & Zhao, L.
National Institute of Allergy and Infectious Diseases
7/1/16 → 6/30/21
Project: Research project
nitazoxanide
Norovirus
Double-Blind Method
Stem Cells
Transplants
Finished
High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
Vanderbilt University, National Institute of Allergy and Infectious Diseases
7/5/17 → 6/30/19
Project: Research project
Adult Stem Cells
Influenza Vaccines
Inactivated Vaccines
Transplants
Hematopoietic Stem Cells
Prot #63623872FLZ2002: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adolescent, Adult, and Elderly Hospitalized Patients W
Janssen Research & Development, LLC
1/19/16 → 8/31/18
Project: Research project
Protocol Number: IRC-005 A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
Social & Scientific Systems, Inc., National Institute of Allergy and Infectious Diseases
10/16/15 → 9/30/18
Project: Research project
Human Influenza
Safety
Hemagglutination
Antiviral Agents
Therapeutics
Protocol IRC002 “A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational anti-Influenza Immune Plasma for the Treatment of Influenza”
Social & Scientific Systems, Inc., National Cancer Institute
4/1/15 → 10/31/15
Project: Research project
Human Influenza
Safety
Oseltamivir
Therapeutics
Mortality
GS-US-218-0108, “A Phase 2b, Randomized, Double-Blind, A Phase 2b, Randomized, Double-Blind, Placebo Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS 5806 in Hematopoietic Cell Transplant (HCT) R
Duke Clinical Research Institute, Gilead Sciences, Inc.
3/24/15 → 3/24/18
Project: Research project
GS-US-218-1502, “A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial V
Duke Clinical Research Institute, Gilead Sciences, Inc.
3/24/15 → 3/24/18
Project: Research project
Prot # GS-US-218-1227: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respiratory Syncytial Virus (RSV) Infection
PPD Development, Gilead Sciences, Inc.
11/13/14 → 11/13/17
Project: Research project
Prot # CMX001-301: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic
PRA Health Sciences, Chimerix, Inc.
9/27/13 → 9/27/18
Project: Research project